1-877-804-4900

Clinical Home Page Slider 2014

Clinical oversight for injured workers to prevent abuse

bannernew

websitebanner1

Ancillary Benefits Management for Workers’ Compensation

websitebanner2

Mobile app for workers compensation

About Us

myMatrixx provides pharmacy and ancillary services for workers’ compensation programs. Our services control costs with proactive clinical oversight throughout the claims process. With one online tool also available in a mobile app, clients can manage claims with real time data and detailed reporting.

Learn more

The Latest

News

Dyloject™ Approved by the U.S. Food and Drug Administration (FDA)

Posted by On January 05, 2015

The U.S Food and Drug Administration (FDA) has approved Dyloject™ (diclofenac sodium) injection by Hospira, Inc. Dyloject™ is a new formulation of diclofenac sodium, which is a proprietary non-steroidal anti-inflammatory drug (NSAID) indicated in adults for the management of mild to moderate pain and management of moderate to severe pain alone or in combination with […]

Kansas 2015 Fee Schedule Controls Pharmacy Spend

Posted by On December 23, 2014

The Kansas Department of Labor, Division of Workers’ Compensation 2015 Schedule of Medical Fees includes two important revisions related to pharmacy spend. For dates of service effective January 1, 2015, physicians must obtain prior approval for compounds and physician dispensed drugs. If the payer approves compound and/or physician dispensed medications, the reimbursement will be the […]

Blog

The Return of Embeda®

Posted by On January 23, 2015

By Alan Rook, PharmD, Clinical Pharmacist It’s Baaack…Embeda® Embeda® will be back in the marketplace on January 26, 2015, after the manufacturer voluntarily recalled the drug almost 4 years ago. On October 17, 2014, the FDA approved new labeling for Embeda® (morphine sulfate and naltrexone hydrochloride) extended-release capsules indicated for pain severe enough to require […]

2014 New Drug Approvals That Will Have an Impact on Workers’ Compensation in 2015

Posted by On January 09, 2015

By Alan Rook, PharmD, Clinical Pharmacist The FDA approved 41 new molecular entities in 2014. Included in this number were 15 drugs targeting orphan diseases, which are rare conditions or diseases that affect fewer than 200,000 individuals in the United States. Both were record setting drug approval numbers for the agency. Of these, there were […]

Visit Blog

Videos

View All